Het
UKEi070-A
General
Cell Line |
|
| hPSCreg name | UKEi070-A |
| Cite as: | UKEi070-A (RRID:CVCL_A0YS) |
| Alternative name(s) |
Het
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
SCVIi074-A (SCVIi599C1) Donor's gene variants: BAG cochaperone 3 Donor diseases: Hypertrophic Cardiomyopathy |
| Last update | 22nd May 2021 |
| User feedback | |
Provider |
|
| Generator | University Medical Center Hamburg-Eppendorf (UKE) |
| Owner | University Medical Center Hamburg-Eppendorf (UKE) |
| Derivation country | Germany |
External Databases |
|
| BioSamples | SAMEA8944455 |
| Cellosaurus | CVCL_A0YS |
| Wikidata | Q108821440 |
General Information |
|
| Publications |
|
| Projects | |
| * Is the cell line readily obtainable for third parties? |
Yes Cell line can only be used in: Cardiovascular research
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Additional restrictions:
MTA required |
| Subclones | |
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
| BioSamples | SAMEA8944456 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Is there other documentation provided to the donor for consenting purposes? | Yes |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | No |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| * Does consent pertain to a specific research project? | Yes |
| Details on restriction to research project | Einfluss verschiedener Therapieverfahren bei hypertropher Kardiomyopathie auf die Beschwerdesymptomatik und körperliche Belastbarkeit der Patienten sowie prognostisch relevante Parameter wie Myokardfibrose, diastolische Dysfunktion und Obstruktion des linksventrikulären Ausflusstraktes. |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Ethical commitee of the Ärztekammer Hamburg |
| Approval number | PV 3501 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type |
Dermal fibroblasts are the major cell type in dermis and are commonly accepted as terminally differentiated cells.
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzymatically
Accutase
|
| O2 Concentration | 5 % |
| Medium |
Other medium:
Base medium: DMEM F12
Main protein source: Human Serum Albumin Serum concentration: 0 % |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Differentiation Potency
In vitro directed differentiation
| Marker | Expressed |
| TNNT2 troponin T2, cardiac type [ Homo sapiens (human) ] |
Yes |
In vitro directed differentiation
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46, XX
Passage number: 19
Karyotyping method:
Nanostring nCounter Karyotype panel
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.